{"id":"NCT01458171","sponsor":"CSL Behring","briefTitle":"Follow-up Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)","officialTitle":"A Multicenter Follow-up Study of Long-term Safety, Tolerability, and Efficacy of Immune Globulin Subcutaneous (Human) IgPro20 in Subjects With Primary Immunodeficiency","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-04","primaryCompletion":"2012-02","completion":"2012-04","firstPosted":"2011-10-24","resultsPosted":"2013-04-09","lastUpdate":"2013-04-09"},"enrollment":23,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Primary Immune Deficiency Disorder"],"interventions":[{"type":"BIOLOGICAL","name":"Immune globulin subcutaneous (Human)","otherNames":["Hizentra"]}],"arms":[{"label":"IgPro20","type":"EXPERIMENTAL"}],"summary":"The objective of this study is to assess the long-term safety, tolerability, and efficacy of IgPro20 in subjects with primary immunodeficiency (PID) as a follow-up to the pivotal study ZLB06\\_002CR (NCT01199705).","primaryOutcome":{"measure":"Median of the Individual Subject's Rate of Adverse Events (AEs) Per Infusion","timeFrame":"24 weeks","effectByArm":[{"arm":"IgPro20","deltaMin":0.167,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":7},"locations":{"siteCount":9,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":23},"commonTop":["Nasopharyngitis","Eczema","Injection site pain","Upper respiratory tract infection","Dental caries"]}}